Form 4: Director Jon Faiz Kayyem Receives Inhibrx Stock Options

Director Jon Faiz Kayyem was granted 15,000 stock options in Inhibrx Biosciences, Inc. with an exercise price of $95.22.

Summary

• Director Jon Faiz Kayyem received a grant of 15,000 stock options for Inhibrx Biosciences, Inc. (INBX) common stock.
• The options have an exercise price of $95.22 per share.
• The options vest fully on June 3, 2027, contingent upon continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Dilutive impact of new option grants on existing shareholders.

Risks

• Vesting is subject to the reporting person's continued service, creating potential retention risk if the director departs before June 3, 2027.

Future Outlook

The options are exercisable starting June 3, 2027, and expire on June 3, 2036, reflecting a long-term incentive structure.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure leadership alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with standard corporate governance practices for mid-cap biotechnology firms.
• The one-year cliff vesting schedule is a common retention mechanism in the industry.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Director to remain in service through June 3, 2027, to satisfy vesting requirements.

Key Dates

Keywords

Inhibrx Biosciences, INBX, Form 4, Stock Options, Insider Trading, Director Compensation